Lokal Anestezik Sistemik Toksisitesi Yönetimi: Güncel Yaklaşım
Özet
Lokal anestezik sistemik toksisitesi (LAST), rejyonel anestezinin en ciddi ve hayatı tehdit eden komplikasyonlarından biridir. Bu durumun tedavisinde intravenöz lipid emülsiyonlarının (ILE) kullanımı, 1998'deki hayvan çalışmalarından 2006'daki ilk başarılı klinik uygulamaya kadar uzanan bir süreçte standart hale gelmiştir. ILE, "lipid sink" (lipid çamuru) teorisiyle lokal anesteziği bağlayarak doku konsantrasyonunu düşürmekte, mitokondriyal enerji üretimini desteklemekte ve sodyum/kalsiyum kanallarını yeniden aktive ederek etki göstermektedir. ASRA ve AAGBI gibi kuruluşlar, LAST yönetimi için güncel rehberler yayımlamış; özellikle %20'lik lipid emülsiyonu kullanımını protokollerine dahil etmiştir. Toksisite belirtileri, ilaç uygulamasından saniyeler sonra veya 60 dakikadan daha geç ortaya çıkabildiğinden, kliniklerde "Lipid Rescue" setlerinin ve tedavi algoritmalarının hazır bulundurulması hayati önem taşır. ILE ayrıca pediatrik vakalarda ve belirli ilaç aşırı dozlarında da etkili bulunmuştur. Güvenli uygulama için blok yapılan her odada resüsitasyon hazırlığının tam olması ve uzman bir ekibin bulunması gerekmektedir.
Local anesthetic systemic toxicity (LAST) is one of the most serious and life-threatening complications of regional anesthesia. The use of intravenous lipid emulsions (ILE) in the treatment of this condition has become standard in a process extending from animal studies in 1998 to the first successful clinical application in 2006. ILE works through the "lipid sink" theory by binding local anesthetics to reduce tissue concentration, supporting mitochondrial energy production, and reactivating sodium/calcium channels. Organizations such as ASRA and AAGBI have published current guidelines for LAST management, specifically incorporating the use of 20% lipid emulsion into their protocols. Since toxicity symptoms can appear within seconds or more than 60 minutes after drug administration, it is vital to have "Lipid Rescue" kits and treatment algorithms readily available in clinics. ILE has also been found effective in pediatric cases and certain drug overdoses. For safe practice, every room where blocks are performed must have complete resuscitation preparation and an expert team present.
Referanslar
Weinberg GL, VadeBoncouer T, Ramaraju GA, Garcia-Amaro MF, Cwik MJ. Pretreatment or resuscitation with a lipid infusion shifts the dose-response to bupivacaine-induced asystole in rats. Anesthesiology. 1998;88(4):1071-5.
Rosenblatt MA, Abel M, Fischer GW, Itzkovich CJ, Eisenkraft JB. Successful use of a 20% lipid emulsion to resuscitate a patient after a presumed bupivacaine-related cardiac arrest. Anesthesiology. 2006;105(1):217-8.
Litz RJ, Popp M, Stehr SN, Koch T. Successful resuscitation of a patient with ropivacaine-induced asystole after axillary plexus block using lipid infusion. Anaesthesia. 2006;61(8):800-1.
Spence AG. Lipid reversal of central nervous system symptoms of bupivacaine toxicity. Anesthesiology. 2007;107(3):516-7.
McCutchen T, Gerancher JC. Early intralipid therapy may have prevented bupivacaine-associated cardiac arrest. Reg Anesth Pain Med. 2008;33(2):178-80.
Cave G, Harvey M, Graudins A. Intravenous lipid emulsion as antidote: a summary of published human experience. Emerg Med Australas. 2011;23(2):123-41.
Ruan W, French D, Wong A, Drasner K, Wu AH. A mixed (long- and medium-chain) triglyceride lipid emulsion extracts local anesthetic from human serum in vitro more effectively than a long-chain emulsion. Anesthesiology. 2012;116(2):334-9.
Li Z, Xia Y, Dong X, Chen H, Xia F, Wang X, et al. Lipid resuscitation of bupivacaine toxicity: long-chain triglyceride emulsion provides benefits over long- and medium-chain triglyceride emulsion. Anesthesiology. 2011;115(6):1219-28.
Waring WS. Intravenous lipid administration for drug-induced toxicity: a critical review of the existing data. Expert Rev Clin Pharmacol. 2012;5(4):437-44.
Hayes BD, Gosselin S, Calello DP, Nacca N, Rollins CJ, Abourbih D, et al. Systematic review of clinical adverse events reported after acute intravenous lipid emulsion administration. Clin Toxicol (Phila). 2016;54(5):365-404.
Vanden Hoek TL, Morrison LJ, Shuster M, Donnino M, Sinz E, Lavonas EJ, et al. Part 12: cardiac arrest in special situations: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2010;122(18 Suppl 3):S829-61.
Neal JM, Neal EJ, Weinberg GL. American Society of Regional Anesthesia and Pain Medicine Local Anesthetic Systemic Toxicity checklist: 2020 version. Reg Anesth Pain Med. 2021;46(1):81-2.
Nolan JP, Soar J, Zideman DA, Biarent D, Bossaert LL, Deakin C, et al. European Resuscitation Council Guidelines for Resuscitation 2010 Section 1. Executive summary. Resuscitation. 2010;81(10):1219-76.
AAGBI Safety Guideline Management of Severe Local Anaesthetic Toxicity. Association of Anaesthetists. 2010.
Vasques F, Behr AU, Weinberg G, Ori C, Di Gregorio G. A Review of Local Anesthetic Systemic Toxicity Cases Since Publication of the American Society of Regional Anesthesia Recommendations: To Whom It May Concern. Reg Anesth Pain Med. 2015;40(6):698-705.
Presley JD, Chyka PA. Intravenous lipid emulsion to reverse acute drug toxicity in pediatric patients. Ann Pharmacother. 2013;47(5):735-43.
Litonius E, Tarkkila P, Neuvonen PJ, Rosenberg PH. Effect of intravenous lipid emulsion on bupivacaine plasma concentration in humans. Anaesthesia. 2012;67(6):600-5.
Weinberg GL. Lipid emulsion infusion: resuscitation for local anesthetic and other drug overdose. Anesthesiology. 2012;117(1):180-7.
